Bolt Biotherapeutics Inc. has synthesized antibody-drug conjugates (ADCs) comprising cysteine-mutant antibodies targeting programmed cell death 1 ligand 1 (CD274; PD-L1) covalently bound to one or more Toll-like receptor 7 (TLR7) and/or TLR8 agonists through a linker reported to be useful for the treatment of cancer.
Bolt Biotherapeutics Inc. has presented new 2-amino-4-carboxamide-benzazepine antibody-drug conjugates (ADCs) comprising antibodies covalently linked to TLR7 and/or TLR8 agonists through a linker and reported to be useful for the treatment of cancer.
The week finished with flurry of biotech IPOs, seven of them, a record number in a single day, according to BioWorld stats. Last year was a record year for IPOs as 106 new offerings were completed and raised $22.5 billion, more than double the previous record of $10.7 billion set in 2018. The seven companies that priced Feb. 5 are anticipating total gross proceeds of about $1.06 billion.
Bolt Biotherapeutics Inc.’s $93.5 million series C round “takes us well into the back end of 2021 and into 2022,” CEO Randall Schatzman told BioWorld, with enough money that the firm is “not impeded in terms of the creativity [we’re] bringing to the table.”